Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS12 | P56730 | 7/20 | 0.67 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.62 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.62 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.62 |
| ▸ | CASP3 | P42574 | 3/20 | 0.61 |
| ▸ | SENP7 | Q9BQF6 | 3/20 | 0.61 |
| ▸ | SENP6 | Q9GZR1 | 3/20 | 0.61 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.57 |
| ▸ | NPC1 | O15118 | 3/20 | 0.57 |
| ▸ | RAB9A | P51151 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.56 |
| ▸ | SCD | O00767 | 1/20 | 0.56 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.56 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.56 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4249984 | 0.89 | PTPN7 (0.63) | PRSS12PTPN7PTPN12PTPN22CASP3 | |
| SCHEMBL4250099 | 0.85 | MAPT (0.70) | PRSS12PTPN7PTPN12PTPN22SMN1; SMN2 | |
| SCHEMBL4918623 | 0.83 | PTPN7 (0.77) | PRSS12PTPN7PTPN12PTPN22CASP3 | |
| SCHEMBL17916672 | 0.83 | PTPN7 (0.67) | PRSS12PTPN7PTPN12PTPN22CASP3 | |
| SCHEMBL29532955 | 0.78 | CASP3 (0.65) | CASP3SENP7SENP6SENP8SMN1; SMN2 | |
| SCHEMBL17251803 | 0.78 | CASP3 (0.65) | CASP3SENP7SENP6SENP8SMN1; SMN2 | |
| SCHEMBL28227108 | 0.77 | CASP3 (0.62) | CASP3SENP7SENP6SENP8SMN1; SMN2 | |
| SCHEMBL16562057 | 0.77 | MAPT (0.72) | PRSS12SMN1; SMN2NPC1RAB9AKMT2A | |
| SCHEMBL23135818 | 0.76 | DYRK1A (0.68) | CASP3SENP7SENP6SENP8SMN1; SMN2 | |
| SCHEMBL4253000 | 0.76 | CASP3 (0.61) | CASP3SENP7SENP6SENP8SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090170914-A1 | Cermide Kinase Modulation | BORNANCIN FREDERIC | 2009-07-02 | — | — | US | claimed |
| EP-2004617-A2 | CERAMIDE KINASE MODULATION | Novartis AG (CH) | 2008-12-24 | — | — | EP | claimed |
| WO-2007112914-A2 | CERAMIDE KINASE MODULATION | NOVARTIS AG (CH) | 2007-10-11 | — | — | WO | claimed |
| US-20090170914-A1 | Cermide Kinase Modulation | BORNANCIN FREDERIC | 2009-07-02 | — | — | US | disclosed |
| US-20090170914-A1 | Cermide Kinase Modulation | BORNANCIN FREDERIC | 2009-07-02 | — | — | US | disclosed |
| US-20090170914-A1 | Cermide Kinase Modulation | BORNANCIN FREDERIC | 2009-07-02 | — | — | US | disclosed |
| EP-2004617-A2 | CERAMIDE KINASE MODULATION | Novartis AG (CH) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007112914-A2 | CERAMIDE KINASE MODULATION | NOVARTIS AG (CH) | 2007-10-11 | — | — | WO | disclosed |
| WO-2007112914-A2 | CERAMIDE KINASE MODULATION | NOVARTIS AG (CH) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170914-A1 | Cermide Kinase Modulation | CERS2, CHKB, SPHK2 | PRSS12 1711/4885PTPN7 2659/4885PTPN12 2674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.